Pediatric Use of Ketoconazole: Safety and Therapeutic Recommendations

Safety Distinction Between Systemic and Topical Formulations

Oral ketoconazole is contraindicated in children because regulatory agencies (FDA/EMA) have issued warnings about severe hepatotoxicity (potentially fatal or requiring liver transplantation), adrenal suppression, QTc prolongation with risk of life‑threatening arrhythmias, and extensive drug‑interaction potential. This contraindication is supported by clinical infectious disease data, dermatology expert reviews, and public health recommendations. 1, 2, 3
The British Association of Dermatologists (BAD) notes that oral ketoconazole was withdrawn from clinical use in the United Kingdom and Europe in 2013 due to its unfavorable safety profile, especially the risk of hepatotoxicity. This reflects expert consensus and regulatory action. 2

Ketoconazole 2 % shampoo should be used only as an adjunctive measure to reduce spore transmission and contagiousness; it is not sufficient as monotherapy for cure of tinea capitis. Systemic antifungal therapy (e.g., griseofulvin or terbinafine) remains mandatory for eradication. This recommendation is based on dermatology guideline literature. 2
Guidelines explicitly advise against using ketoconazole shampoo as the sole treatment for tinea capitis. The BAD reinforces this position. 2

When a child is receiving systemic medications, clinicians should avoid concomitant use of other hepatotoxic agents, as the primary concern for liver injury pertains to oral azole antifungals rather than topical ketoconazole shampoo. This precaution is drawn from infectious disease safety alerts and public health reports. 1, 4

First‑line systemic options for pediatric tinea capitis include griseofulvin or terbinafine (the latter licensed for children > 12 years in the United Kingdom); fluconazole or itraconazole may be used as alternative agents. These recommendations are outlined in dermatology guideline publications. 2

For infants under six months, apply ketoconazole 2 % shampoo to the affected scalp, leave it in contact for 3–5 minutes, then rinse thoroughly. This recommendation is based on pediatric guideline guidance for optimal antifungal activity while limiting exposure. 5

The American Academy of Pediatrics strongly advises against oral (systemic) ketoconazole in pediatric patients because of FDA/EMA warnings about hepatotoxicity, adrenal suppression, and significant drug interactions. This caution applies only to systemic formulations; topical shampoo and cream have demonstrated a favorable safety record in infants. 6

According to the British Association of Dermatologists, topical agents such as ketoconazole 2 % shampoo are intended primarily to reduce spore transmission in tinea capitis and are not sufficient as sole therapy for scalp ringworm, which requires systemic antifungal treatment.
For uncomplicated infantile seborrheic dermatitis (cradle‑cap), topical ketoconazole shampoo alone is appropriate and effective as a steroid‑sparing option. 7